Mentoring in Translational Research in Interstitial Lung Diseases

间质性肺疾病转化研究的指导

• 批准号: 9270690
• 负责人: Wonder P. Drake
• 金额: $ 10.69万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-02-15 至 2021-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9270690
• 关键词: Antigens; Antimycobacterial Agents; Biological Assay; CD28 gene; CD4 Positive T Lymphocytes; Candidate Disease Gene; Cell physiology; Cessation of life; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Communicable Diseases; Cryptococcus neoformans infection; DNA Methylation; Data Collection; Defect; Disease; Disease Progression; Down-Regulation; Employee Strikes; Epigenetic Process; Family; Foundations; Functional disorder; Funding; Gene-Modified; Genes; Genomics; Grant; Granuloma; Granulomatous; HIV; Health; Helicobacter pylori; Immune; Immunologics; In Vitro; Inflammatory; Interleukin-2; Interstitial Lung Diseases; Intervention Studies; Investigation; K-Series Research Career Programs; Laboratories; Lead; Leadership; Leucine; Ligation; Link; Lung; Lung diseases; Manuscripts; Mass Spectrum Analysis; Mediator of activation protein; Mentored Research Scientist Development Award; Mentors; Microarray Analysis; Midcareer Investigator Award in Patient-Oriented Research; Modification; Molecular; Morbidity - disease rate; Nature; Outcome; Pathogenesis; Pathway interactions; Patients; Peripheral Blood Mononuclear Cell; Phase; Placebo Control; Positioning Attribute; Principal Investigator; Publications; Randomized; Receptor Signaling; Regulation; Reporting; Research; Research Design; Research Project Grants; Resolution; Role; Sarcoidosis; Scientist; Signal Transduction; Stomach; Susceptibility Gene; T Cell Receptor Signaling Pathway; T-Cell Receptor; T-Lymphocyte; Therapeutic; Therapeutic Intervention; Time; Training; Transcription Factor AP-1; Translating; Translational Research; Translations; Tuberculosis; Universities; Up-Regulation; Vital capacity; Wood material; Work; career; clinical investigation; common cellular transcription factor ATF; cytokine; design; epigenomics; experience; immune function; medical schools; member; microbial; microorganism antigen; mid-career faculty; mortality; mouse model; mycobacterial; novel therapeutic intervention; novel therapeutics; patient oriented research; programs; research and development; response; restoration; transcription factor

 DESCRIPTION (provided by applicant): This is a proposal to provide protected time for Dr. Drake to provide greater mentoring to junior clinical investigators as well as increase her capacity to expand her clinical investigations in interstitial lung disease. Dr. Drake proposes a mentoring plan which will facilitate the effective transition from junior clinical investigator to research scientist. She provides a detailed description of her own augmentation of further training in clinical trial implementation. Her current research projects are thematically linked through their focus on molecular and immunologic determinants of sarcoidosis clinical outcome for the purpose of identifying novel therapeutic interventions. In particular, her research focuses on the contribution of mycobacterial induction of T cell dysfunction to sarcoidosis disease progression, and the capacity of antimycobacterial therapy to restore T cell function. Trainees have been involved in many aspects of the ongoing patient-oriented research including study design, patient accrual, data collection, laboratory assays and analysis and presentation of findings. The transformative nature of the proposal to investigate the therapeutic utility of PD-1 is that it allows translation of molecular mechanisms identified at the bench to immune function within the host, and ultimately to a clinical endpoint associated with sarcoidosis mortality, absolute FVC.